Background and Aims: Mepolizumab, a humanized monoclonal antibody against interleukin-5 (IL-5), showed efficacy in previous clinical trials in terms of reduction of exacerbations and the oral corticosteroidsparing effect in severe eosinophilic asthma. An understanding of the effectiveness and safety of mepolizumab in real world setting is needed.
Methods:
The analysis includes patients with severe asthma who received mepolizumab at least twice at our institution from July 2016 to May 2018. We reviewed blood eosinophil counts, the number of exacerbations, the corticosteroid dose, and safety data during the follow-up. We also analyzed the asthma control scores of Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), and the QOL scores of Asthma Quality of Life Questionnaire (AQLQ) and Asthma Health Questionnaire (AHQ).
Results: Subjects are 19 patients with median age of 65 (39-81). All of them had received asthma treatment equivalent to GINA step 4/5, 12 with oral corticosteroid, 7 with a history of anti-IgE antibody, and 3 with completion of bronchial thermoplasty. At follow up, the rate of exacerbation decreased in 15 (80%) patients and all of the patients (100%) showed the decrease of eosinophil counts. Seven (37%) patients reduced oral prednisone more than 50%. Of 6 patients followed up with questionnaires, asthma control scores improved in both two questionnaires; ACQ from 2.3 (1.6-4.6) to 1.6 (0.6-2.8), ACT from 13 (9-21) to 18.5 (13-20) . Regarding QOL scores, AQLQ improved from 3.5 (2.9-4.5) to 2.2 (3.5-5.7) and AHQ from 52.5 (42-75) to 30 (16-65), indicating better control and QOL. Eight patients had discontinued the treatment, 5 switched to another anti-IL-5 antibody, 1 due to achieving good control, 2 due to adverse events (1 with liver injury and 1 with decreased vision).
Conclusion:
Mepolizumab is effective in reducing asthma exacerbation and the oral corticosteroid dose, and improving asthma control and health-related QOL in real world setting. Background and Aims: Allergic asthma is a chronic airway inflammatory disease, and its pathophysiological mechanism has not yet been fully elucidated. Metabolomics happens to be a powerful tool for discovering new biomarkers and resolving disease pathophysiology. Therefore, our aim was to use UHPLC-Q-TOF-MS to investigate the serum lipid metabolomic differences between patients and healthy people. Then, the changes of eicosanoid metabolism in patients with allergic asthma before and after routine drug treatment were analyzed.
Methods: Thirty patients with allergic asthma were enrolled in the asthma group, and another 30 healthy individuals were recruited as the healthy group. Serum was collected, sample pretreated and derivatized, and used for non-targeted lipid metabolomics detection and analysis. Then, based on eicosanoid-targeted metabolomics, the changes of serum target metabolites in 25 children with allergic asthma before and after routine drug treatment were retrospectively analyzed.
Results: We detected 278 lipid metabolites using the +ESI and found a suitable OPLS-DA model for distinguishing asthma group from healthy group (R2 = 0.556, Q2 = 0.953). Differential metabolite analysis showed that eicosanoid levels in the asthma group were significantly higher than those in the healthy group (P < 0.05), especially HETEs. From the ROC curve, it can be concluded that the differential metabolite with the largest AUC is 12(S)-HETE (AUC = 0.983, 95% CI = 0.941-1.000). Metabolic pathway enrichment analysis showed that differential metabolites are concentrated in arachidonic acid metabolic pathways, and this pathway is mostly associated with inflammatory reactions and oxidative stress. After routine drug treatment, the target metabolites were significantly decreased (P < 0.05), and the LOX-mediated arachidonic acid metabolism pathway was significantly downregulated.
The results of this study suggest that HETEs are potential biomarkers for allergic asthma. GPx may be a key enzyme that links the inflammatory response and oxidative stress of allergic asthma, and it may be a new target for anti-inflammatory and anti-oxidative therapy for allergic asthma. 
